Review



off-target cas9 edits  (Chrom Tech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Chrom Tech off-target cas9 edits
    Multiplex <t>CRISPR-Cas9</t> and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)
    Off Target Cas9 Edits, supplied by Chrom Tech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/off-target+cas9+edits/pmc08935473-19-10-32?v=Chrom+Tech
    Average 90 stars, based on 1 article reviews
    off-target cas9 edits - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "A CRISPR Odyssey into Cancer Immunotherapy"

    Article Title: A CRISPR Odyssey into Cancer Immunotherapy

    Journal: The CRISPR Journal

    doi: 10.1089/crispr.2020.29090.ede

    Multiplex CRISPR-Cas9 and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)
    Figure Legend Snippet: Multiplex CRISPR-Cas9 and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)

    Techniques Used: Multiplex Assay, CRISPR, Derivative Assay, Transduction



    Similar Products

    target crispr cas9 editing events  (Integrated DNA Technologies)
    99
    Integrated DNA Technologies target crispr cas9 editing events
    Target Crispr Cas9 Editing Events, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/off-target+cas9+edits/pmc06876493-97670-8-33?v=Integrated+DNA+Technologies
    Average 99 stars, based on 1 article reviews
    target crispr cas9 editing events - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    off-target cas9 edits  (Chrom Tech)
    90
    Chrom Tech off-target cas9 edits
    Multiplex <t>CRISPR-Cas9</t> and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)
    Off Target Cas9 Edits, supplied by Chrom Tech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/off-target+cas9+edits/pmc08935473-19-10-32?v=Chrom+Tech
    Average 90 stars, based on 1 article reviews
    off-target cas9 edits - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    off target crispr cas9 editing events  (Integrated DNA Technologies)
    99
    Integrated DNA Technologies off target crispr cas9 editing events
    Multiplex <t>CRISPR-Cas9</t> and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)
    Off Target Crispr Cas9 Editing Events, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/off-target+cas9+edits/10__1016_slash_j__ymthe__2019__04__004-3325-7-28?v=Integrated+DNA+Technologies
    Average 99 stars, based on 1 article reviews
    off target crispr cas9 editing events - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Multiplex CRISPR-Cas9 and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)

    Journal: The CRISPR Journal

    Article Title: A CRISPR Odyssey into Cancer Immunotherapy

    doi: 10.1089/crispr.2020.29090.ede

    Figure Lengend Snippet: Multiplex CRISPR-Cas9 and lentiviral editing of T cells. Schematic of genetic engineering of patient-derived T cells depicting lentiviral transduction of the NY-ESO-1 TCR transgene and delivery of Cas9/gRNA ribonucleoprotein complexes targeting genes for endogenous TCR chains—TCRα and TCRβ—and PD-1 (TRAC, TRBC, and PDCD1, respectively). The final desired T cell product has a synthetic NY-ESO-1 TCR and no TCAR, TCBR, or PD-1, but other editing products include T cells with mixed edits. Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al.2)

    Article Snippet: Important safety considerations for clinical application include chromosomal translocations and off-target Cas9 edits, as well as immune response to the delivered products. gRNA, guide RNA; TCR, T-cell receptor; PD-1, programmed death protein-1; Chrom., Chromosomal. (Image adapted from Stadtmauer et al . 2 ) For medical applications, reducing the chance of toxicity of infused cell products is the top priority.

    Techniques: Multiplex Assay, CRISPR, Derivative Assay, Transduction